Agenus (AGEN) Stock: Buy, Sell, or Hold?
AGEN - Agenus Inc.
$8.36
0.03 (0.36%)
â˛
5d:
-2.11%
30d:
+3.34%
90d:
+145.16%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When AGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: AGEN is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: AGEN is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: AGEN is currently trading at $8.36, which is considered fair relative to its 30-day fair value range of $7.24 to $8.82. From a valuation perspective, the stock is trading at a discount (Forward PE: -76.0) compared to its historical average (5.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AGEN is in a strong uptrend. Immediate support is located at $7.60, while resistance sits at $10.31.
Market Sentiment: AGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.33 (+215.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AGEN is in a strong uptrend. Immediate support is located at $7.60, while resistance sits at $10.31.
Market Sentiment: AGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.33 (+215.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.24 -
$8.82
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding AGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 215.0% below Wall St target ($26.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.24 -
$8.82
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.60
Resistance Level
$10.31
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-76.00
Wall Street Target
$26.33
(+215.0%)
Revenue Growth (YoY)
34.4%
Profit Margin
69.3%
PE vs Historical
-76.0 vs 5.1
CHEAP
Share & Embed Analysis
Last updated: October 04, 2026 12:31 AM ET
Data refreshes hourly during market hours. Next update: 1:31 AM
Data refreshes hourly during market hours. Next update: 1:31 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
Advanced AGEN Option Strategies
Professional options setups generated by AI based on today's AGEN price and gamma walls.
